Sales -1% y-o-y, -3% vs. ABGSCe EBIT of SEK 63m, 75% vs.
Redeye retains its positive view of Carasent following a solid Q3 report showing accelerating organi...
Redeye continues to see a compelling long-term investment case.
Atria delivered a strong Q3, with adjusted EBIT 35% above LSEG Data & Analytics consensus.
'24e-'26e sales up 3-2% In line to reach annual growth target of ~50% Revised FVR of SEK 30-45 (25-4...
Redeye provides a research update following the Q4 report recently published by Newbury.
Hyresintäkterna sjönk något till 847 mkr, främst drivet av tidigare avyttrade fastigheter.
Pharma Equity Group (“PEG” or “the Company”) announced on Wednesday, October the 23rd, that the Comp...
Organic growth of 31%, +6pp vs. ABGSCe Significant EBITDA improvement Likely positive consensus esti...
EBIT SEK 40m vs. ABG SEK 47m — higher costs, lower volumes Q4 likely weaker driven by maintenance Co...
Redeye updates its estimates and valuation following Lifco releasing its Q3 2024 report.
Redeye anticipates the Lifecare division to maintain its solid performance in Q3 2024, though weaker...
Redeye’s first comments follow this morning’s Q3 report from Tagmaster.
Ahead of CapMan's Q3 report due on 7 November, we revise our estimates to reflect the divestment of ...
Administer announced yesterday that it will lower its revenue guidance to EUR 74-76m, while narrowin...
